Oxurion (TBGNF) Stock Price, News & Analysis

Company Overview

Oxurion is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutic solutions for retinal disorders. Originally founded as ThromboGenics in Belgium, the company rebranded as Oxurion in 2019 to reflect its renewed focus on ocular diseases. Oxurion’s research pipeline centers on innovative approaches to treating conditions such as diabetic macular edema (DME), retinal vein occlusion (RVO), and other vision-threatening vascular and inflammatory retinal diseases.

The company’s lead investigational product, THR-149, is a first-in-class plasma kallikrein inhibitor designed to reduce vascular leakage, inflammation, and edema in the eye. Oxurion has advanced THR-149 through Phase I/II trials, demonstrating safety and encouraging signs of efficacy in patients with DME who are unresponsive to current standard-of-care treatments. In addition to THR-149, Oxurion is exploring other proprietary compounds and drug delivery platforms aimed at improving patient outcomes by targeting novel mechanisms implicated in retinal disease progression.

Headquartered in Leuven, Belgium, Oxurion maintains a presence in key European and North American markets, collaborating with leading ophthalmology centers and contract research organizations to conduct clinical trials. The company’s global reach enables it to engage with regulatory authorities across multiple jurisdictions to expedite development timelines and broaden potential patient access. Oxurion also partners with academic institutions to leverage translational research and foster innovation in ocular therapeutics.

Under the leadership of CEO Rudi Pauwels, an experienced biotech entrepreneur and virologist, Oxurion continues to build a robust pipeline and strategic collaborations. The management team combines expertise in drug discovery, clinical development, and commercialization within the ophthalmology sector. By maintaining a clear focus on underserved retinal diseases and leveraging its scientific capabilities, Oxurion aims to deliver breakthroughs that can preserve and restore vision for patients worldwide.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.17 to $0.17
• 52-Week Range: $0.17 to $0.29
• Volume: N/A
• Average Volume: 440 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TBGNF Stock Analysis - Frequently Asked Questions

How have TBGNF shares performed this year?

Oxurion's stock was trading at $0.17 at the beginning of 2025. Since then, TBGNF stock has increased by 0.0% and is now trading at $0.17.

How do I buy shares of Oxurion?

Shares of TBGNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TBGNF
• CIK: N/A
• Web: www.oxurion.com
• Phone: (321) 675-1317
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A